Business
BioElectronics Corporation: Letter to Shareholders
BioElectronics Corporation: Letter to Shareholders.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n \n \n BioElectronics Corporation: Letter to Shareholders\n \n \nBioElectronics Corporation: Letter to Shareholders\n \n FREDERICK, MD--(Marketwired - Oct 24, 2013) - BioElectronics Corporation (OTC Pink: BIEL) presents letter to shareholders.\n Dear Fellow Shareholders:\n I want to report on the progress we're making on the four-part growth strategy I articulated in my last letter to shareholders.?I said that the path to success for BioElectronics would focus on the following four ongoing efforts:\n 1. Executing an aggressive marketing and sales program in the large European markets and select other global markets; \n 2. Developing political and public support to compel the US FDA to recognize our therapeutic solution to the dire need for an alternative to the devastating side effects and addictions of OTC and prescription drugs; \n 3. Continuing clinical research to develop new products and substantiate our efficacy in more indications; and,\n 4. Lowering our cost of capital to finance expansion.\n First -- Global Marketing Program\n Earlier this year we engaged the Gro-International team to position our products for European sales and despite the slow global recovery they have made progress.?We shipped our ActiPatch? Therapy product this month to Boots, the leading pharmacy chain in the United Kingdom and a role model in the industry.?Boots pharmacies are a strategic member of the Boots-Alliance, the world's first global pharmacy-led health and well-being enterprise.?Walgreens, the largest drugstore chain in the US, acquired 45% of Alliance-Boots in August.?ActiPatch will be available to UK customers on Boots.com on November 1, and will be on store shelves around the country starting next week.?We are using the Gro-International team and the UK firm, Fuel PR International to facilitate this launch.\n The innovation award we won from OTC Bulletin in March has yielded more than a good-looking plaque.?Our products caught the attention of several interested parties including three of Europe's largest pharmaceutical companies.?We are actively exploring distribution and co-branding licensing proposals with all three. In each case these proposals offer significant potential advantages to the company.?The most immediate would be product sales to companies with well-established, funded marketing and sales channels, and licensing agr...